Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526603 · ClinicalTrials.gov registry record · NA
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01526603 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 13 participants.
The verdict
NCT01526603, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.
Interventions
- DRUG Carboplatin
- RADIATION Radiation therapy
- BIOLOGICAL Autologous stem cell infusion
- BIOLOGICAL Granulocyte colony stimulating factor
- DRUG Isotretinoin (13-cis-retinoic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2023-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526603
The ClinicalTrials.gov registry entry for NCT01526603 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01526603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526603 about?
NCT01526603 is a clinical study titled "High Dose Chemotherapy and Autologous Transplant for Neuroblastoma". This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.
What is the current status of trial NCT01526603?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2012-03-28. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT01526603?
The interventions under investigation include: Carboplatin (DRUG), Radiation therapy (RADIATION), Autologous stem cell infusion (BIOLOGICAL), Granulocyte colony stimulating factor (BIOLOGICAL), Isotretinoin (13-cis-retinoic acid) (DRUG).
Who is sponsoring clinical trial NCT01526603?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.